Ebola

Maxwell Biosciences Announces Promising Activity of Claromer Compound Against Ebola Virus in a Research Study

Retrieved on: 
Thursday, November 2, 2023

The data showed one of Maxwell's Claromer compounds is active against Ebola virus within the critical time frame required to address Ebola virus disease progression.

Key Points: 
  • The data showed one of Maxwell's Claromer compounds is active against Ebola virus within the critical time frame required to address Ebola virus disease progression.
  • Once a human is infected, Ebola virus disease can be lethal within 4-5 days.
  • Maxwell is currently developing its Claromer drug platform, which has the potential to replace almost all antibiotics, antifungals and antivirals.
  • Since the first outbreak in Africa in 1976, several outbreaks and epidemics of Ebola virus have occurred in Western and Central Africa.

Highlight from Kinnos Recognized as One of TIME’s Best Inventions of 2023

Retrieved on: 
Tuesday, October 24, 2023

BROOKLYN, N.Y., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Kinnos today announced that Highlight®, its novel technology for colorizing disinfectant wipes, earned a special mention in the TIME Best Inventions of 2023 list.

Key Points: 
  • BROOKLYN, N.Y., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Kinnos today announced that Highlight®, its novel technology for colorizing disinfectant wipes, earned a special mention in the TIME Best Inventions of 2023 list.
  • New threats like Candida auris continue to emerge just as multiple studies show that less than 50% of hospital surfaces are properly cleaned.
  • The result is a list of inventions that are changing how we live, work, play, and think about what’s possible.
  • Highlight from Kinnos was also recently recognized in the Fast Company 2023 Innovation by Design awards.

World Emerging Infectious Disease Diagnostics Market Research Report 2023: Respiratory Infections Take Center Stage in Infectious Disease Diagnostics Post-COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 25, 2023

The emergence of the COVID-19 pandemic has had a profound and far-reaching impact on infectious disease diagnostics worldwide.

Key Points: 
  • The emergence of the COVID-19 pandemic has had a profound and far-reaching impact on infectious disease diagnostics worldwide.
  • North America, encompassing both the United States and Canada, currently holds the largest share in the global emerging infectious disease diagnostics market.
  • Some of the common bacterial infections include respiratory infections such as tuberculosis and streptococcal infections and sexually transmitted infections (STIs) such as chlamydia, gonorrhea, and syphilis.
  • Hospitals and clinics play a critical role in the field of infectious disease diagnostics, serving as important centers for patient evaluation and testing.

Global Patient Temperature Monitoring Market Set for Remarkable Growth as Demand Surges for Advanced Monitoring Devices - ResearchAndMarkets.com

Retrieved on: 
Monday, October 9, 2023

No.

Key Points: 
  • No.
  • of Cases and Deaths Due to Ebola Virus Disease (EVD) Worldwide: 2014 to June 2017
    Global Population Statistics for the 65+ Age Group by Select Countries: 2019
    Total Preterm Births (in Percentage) in the US: 2010-2018E
    Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040

European Commission Expands Merck’s ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older

Retrieved on: 
Thursday, September 7, 2023

The vaccine was previously approved for use in the European Union (EU) for individuals 18 years of age or older.

Key Points: 
  • The vaccine was previously approved for use in the European Union (EU) for individuals 18 years of age or older.
  • “Ebola virus disease is severe and potentially life-threatening for both children and adults.
  • INDICATIONS AND USAGE IN THE U.S.
    ERVEBO® is indicated for the prevention of disease caused by Zaire ebolavirus in individuals 12 months of age and older.
  • Effectiveness of the vaccine when administered concurrently with antiviral medication, immune globulin (IG), and/or blood or plasma transfusions is unknown.

RedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®)

Retrieved on: 
Tuesday, September 5, 2023

TEL-AVIV, Israel and RALEIGH, N.C., Sept. 5, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) had issued a Notice of Allowance for a new opaganib[1] patent covering sphingosine kinase 2 inhibition treatment for Ebola virus disease, supporting opaganib pro tection until October 2035. The Company also announced that the European Patent Office has granted RHB-102 (BEKINDA)[2] a new patent, covering ondansetron extended-release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms. This new patent is expected to provide protection of RHB-102 across multiple indications until March 2035.

Key Points: 
  • USPTO issues Notice of Allowance for a new opaganib patent covering sphingosine kinase 2 inhibition treatment for Ebola virus disease, supporting opaganib protection until October 2035
    Additionally, European Patent Office grants new RHB-102 patent covering ondansetron extended-release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms, providing protection of RHB-102 across multiple indications until March 2035
    TEL-AVIV, Israel and RALEIGH, N.C., Sept. 5, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) had issued a Notice of Allowance for a new opaganib[1] patent covering sphingosine kinase 2 inhibition treatment for Ebola virus disease, supporting opaganib pro tection until October 2035.
  • The Company also announced that the European Patent Office has granted RHB-102 (BEKINDA)[2] a new patent, covering ondansetron extended-release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms.
  • This new patent is expected to provide protection of RHB-102 across multiple indications until March 2035.

Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position

Retrieved on: 
Tuesday, August 8, 2023

GAITHERSBURG, Md., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced it is reducing investment in and de-emphasizing focus on growth in its CDMO services business. As a result, Emergent is reducing operations at its Bayview facility in Baltimore, Maryland.

Key Points: 
  • Going forward, Emergent will focus on its core products business – medical countermeasures and NARCAN® Nasal Spray –and on delivering for its existing customers, including the U.S. and allied governments.
  • Emergent will maintain a level of operations at both Bayview and Canton to ramp up production in response to new demand.
  • “The actions we are taking will further strengthen our core products business and financial foundation,” said Emergent interim Chief Executive Officer Haywood Miller.
  • As a result of the strategic shift away from Emergent’s services business, the company is eliminating the chief operating officer (COO) role.

U.S. FDA Approves Merck’s ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older

Retrieved on: 
Thursday, August 3, 2023

The vaccine was previously approved for use in individuals 18 years of age and older.

Key Points: 
  • The vaccine was previously approved for use in individuals 18 years of age and older.
  • ERVEBO is currently authorized for use in the European Union (EU) for individuals 18 years of age and older.
  • ERVEBO® is indicated for the prevention of disease caused by Zaire ebolavirus in individuals 12 months of age and older.
  • Effectiveness of the vaccine when administered concurrently with antiviral medication, immune globulin (IG), and/or blood or plasma transfusions is unknown.

Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola

Retrieved on: 
Monday, July 31, 2023

“For almost 25 years, Emergent has tackled the most serious diseases to assist governments in their preparedness and response strategies,” said Dr. Kelly Warfield, senior vice president, science and development at Emergent.

Key Points: 
  • “For almost 25 years, Emergent has tackled the most serious diseases to assist governments in their preparedness and response strategies,” said Dr. Kelly Warfield, senior vice president, science and development at Emergent.
  • “Ebola virus has the ability to emerge unexpectedly posing a risk to global health.
  • If all option periods are exercised, the total contract value will be valued at up to approximately $704 million.
  • This project has been funded in whole or in part with federal funds from HHS; ASPR; BARDA, under contract number 75A50123C00037.

AIM ImmunoTech Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments

Retrieved on: 
Monday, June 12, 2023

Ampligen continues to demonstrate significant potential across multiple types of cancers, immune disorders and viral diseases.

Key Points: 
  • Ampligen continues to demonstrate significant potential across multiple types of cancers, immune disorders and viral diseases.
  • AMP-270 is expected to enroll approximately 90 subjects in up to 30 centers across the United States and Europe.
  • The Company is recruiting patients for its AMP-270 Phase 2 study of Ampligen as a therapy for LAPC.
  • The lead site at the University of Nebraska Medical Center is now open and actively working to enroll patients.